COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

High-dose Cyclophosphamide for Severe Refractory Crohn Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01836289
Recruitment Status : Withdrawn (Too difficult to recruit given new Crohn's medications approved)
First Posted : April 19, 2013
Last Update Posted : August 13, 2018
Information provided by (Responsible Party):
Johns Hopkins University

Brief Summary:

This research is being done to see if people with Crohn's disease who receive high-dose cyclophosphamide have an improvement of their disease, how long the benefit may last, and how safe cyclophosphamide is. This study is for patient with medically refractory disease that is not easily amenable to surgery.

Cyclophosphamide is an FDA-approved chemotherapy medication that is also frequently used to treat autoimmune illness; use of cyclophosphamide for autoimmune disease is not approved by the FDA. An autoimmune illness is when the immune system mistakenly attacks self, targeting the cells, tissues, and organs of a person's own body. There are many different autoimmune diseases and they can each affect the body is different ways. Crohn's disease is an autoimmune disease that primarily affects the small and large intestines. High dose-cyclophosphamide has been successfully used to treat Crohn's, primarily as part of a conditioning regimen for autologous stem cell transplantation. However, this therapy is limited in Crohn's because of it's serious infectious risks. This current study involves using high-dose cyclophosphamide without need for stem cell transplantation. This appears to be a safer approach in other autoimmune illnesses that have been studied.

Condition or disease Intervention/treatment Phase
Crohn's Disease Crohn Disease Drug: High-dose Cyclophosphamide Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: High-dose Cyclophosphamide for Severe Refractory Crohn Disease
Study Start Date : March 2015
Estimated Primary Completion Date : March 2018
Estimated Study Completion Date : March 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Crohn's Disease

Arm Intervention/treatment
Experimental: High-dose Cyclophosphamide
High-dose Cyclophosphamide
Drug: High-dose Cyclophosphamide
Other Names:
  • Endoxan®
  • Cytoxan®
  • CTX
  • Neosar®
  • Procytox®
  • Revimmune™

Primary Outcome Measures :
  1. Evaluation of safety of the High-Dose Cyclophosphamide (HDC) protocol [ Time Frame: 3 Years ]
    Tablulation of serious adverse events associate with the HDC protocol

Secondary Outcome Measures :
  1. HDC-Induced Steroid-free remission [ Time Frame: 3 Years ]
    To determine if HDC therapy can induce and maintain a steroid-free clinical remission (defined as CDAI<150) at 12 and 52 weeks. Applies to patients without an existing ostomy.

  2. HDC-Induced Mucosal Healing [ Time Frame: 3 Years ]
    To determine if HDC therapy can induce sustained mucosal healing defined as absence of ulcers on colonoscopy

  3. Improvement in patient reported quality of life [ Time Frame: 3 years ]
    To determine if HDC can lead to improvement in inflammatory bowel disease questionnaire scores at weeks 12 and 52

  4. Molecular Mechanisms of High-dose Cyclophosphamide (HiCy) Therapy [ Time Frame: 3 Years ]
    To investigate the molecular mechanisms by which HiCy therapy works by analyzing the effects of HiCy on the levels of serum cytokines (using multiplex ELISA), and correlate the data with clinical activity and treatment response.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ≥ 18 years of age, males and females will be eligible
  • Moderate to severe Crohn's Disease (CD) with CDAI > 220, in addition to evidence of ulceration on ileocolonoscopy or active disease on small bowel imaging (in patients with an ostomy, CDAI criteria do not apply)
  • Disease progression (primary or secondary non-responder, or reaction to) to at least one anti-tumor necrosis factor (TNF) agent (infliximab, adalimumab, certolizumab pegol), and additionally had disease progression despite one of the following immunosuppressant drugs: azathioprine, 6-mercaptopurine, methotrexate, cyclosporine, natalizumab, vedolizumab
  • Willingness to participate in a clinical trial
  • Approval by Enrollment Panel, who will collectively decide on the appropriateness of possible study study participants

Exclusion Criteria:

  • Pregnant or nursing women
  • Sexually active men and women who do not agree to use effective means of birth control during treatment period
  • Evidence of primarily fibrostenosing disease without active inflammatory disease on disease staging
  • Co-morbid conditions including cardiac disease with an ejection fraction of < 45%, chronic renal failure with serum creatinine > 2.0, liver disease with total bilirubin > 2.0, (excluding hyperbilirubinemia secondary to Gilbert's disease) or transaminitis > 3x upper limit of normal.
  • History of serious allergic reaction to cyclophosphamide
  • History of malignancy in the last 5 years (excluding non-melanomatous skin cancers)
  • Patients who are pre-terminal
  • Toxic megacolon
  • Active infection
  • White blood cell count < 3000 cells/ul, platelets < 100K / ul, hemoglobin < 10.0 g/dL
  • Any use of thiopurines, methotrexate or anti-TNF agents in the previous four weeks prior to treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01836289

Sponsors and Collaborators
Johns Hopkins University
Layout table for investigator information
Principal Investigator: Mark G. Lazarev, MD Johns Hopkins University

Layout table for additonal information
Responsible Party: Johns Hopkins University Identifier: NCT01836289    
Other Study ID Numbers: NA_00052668
First Posted: April 19, 2013    Key Record Dates
Last Update Posted: August 13, 2018
Last Verified: August 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Crohn Disease
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists